TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically proven adenocarcinoma of the breast~* Phase I: Measurable or evaluable disease~* Phase II: Bidimensionally measurable disease~* No CNS metastases~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 65 and over~Sex:~* Female~Menopausal status:~* Postmenopausal~Performance status:~* ECOG/SAKK 0-2~Life expectancy:~* At least 12 weeks~Hematopoietic:~* Normal peripheral blood counts~Hepatic:~* AST no greater than 2 times upper limit of normal (ULN) (no greater than 3 times ULN if liver metastases present)~Renal:~* Creatinine no greater than 1.5 times ULN~Other:~* No other prior or concurrent malignancy except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix~* No peripheral neuropathy grade 2 or higher~* No cognitive impairment or severe psychiatric disorder~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* More than 6 months since prior adjuvant chemotherapy~* No prior chemotherapy for metastatic or locally advanced disease~* No other concurrent chemotherapy~Endocrine therapy:~* Prior hormonal therapy for metastatic disease allowed~* No continuous concurrent steroids~* No concurrent systemic endocrine therapy for breast cancer~* No other concurrent endocrine therapy~Radiotherapy:~* No concurrent radiotherapy involving greater than 30% of bone marrow or mucosa~* Radiotherapy to nonindicator lesion allowed~Surgery:~* Not specified~Other:~* Bisphosphonates allowed if indicator lesion in nonbone site

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.~* Active SLE disease.~* Autoantibody-positive.~* Have antibodies with titers \>1.0 microgram (mcg)/mL to no more than 9 of the 23 serotypes present in the pneumococcal vaccine.~* Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures.~Key Exclusion Criteria:~* Pregnant or nursing.~* Have received any prior treatment with belimumab.~* Have received a live vaccine within the past 30 days.~* Have received a pneumococcal vaccination with the past 5 years.~* Have a history of severe allergic reaction to a vaccine, contrast agents (such as those used for x-rays and CT scans), or biological medicines.~* Have required management of an infection or have had infections that keep coming back within the past 60 days.~* Hepatitis B: Serologic evidence of Hepatitis B (HB) infection based on the results of testing for HB surface antigen (HBsAg) and anti-HB core antibody (anti-HBc):~  * Subjects positive for HBsAg are excluded.~ * Subjects negative for HBsAg but positive for anti-HBc, regardless of anti-HBs antibody status, are excluded.~* Hepatitis C: Positive test for Hepatitis C antibody.~* Known human immunodeficiency virus (HIV) infection.~* Have current drug or alcohol abuse or dependence.~* Have a Grade 3/4 immunoglobulin (Ig)G deficiency (IgG level \<400 milligrams \[mg\]/ deciliter \[dL\]) or IgA deficiency (IgA level \<10 mg/dL).~* Subjects who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or suicidal ideation with some intent to act in the last 2 months or who in the investigator's judgment, pose a significant suicide risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belimumab plus Early Vaccination (Type: EXPERIMENTAL): Belimumab plus Early Vaccination
- Belimumab plus Late Vaccination (Type: EXPERIMENTAL): Belimumab plus Late Vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female pupil~* attends selected school~* born in 1998 if enrolled in school selected for age-based delivery~* attending standard (class) 6 if enrolled in school selected for class-based delivery~Exclusion Criteria:~* has not previously received HPV vaccine~* has not participated in previous HPV vaccine trials

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Class-based delivery (Type: OTHER): All girls attending standard 6 in schools selected for class-based vaccine delivery
- Age-based delivery (Type: OTHER): All girls born in 1998 attending schools selected for age-based delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be undergoing their first cardiac allograft transplant~* Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to transplantation~* Women of childbearing potential must use two reliable forms of contraception simultaneously. Effective contraception must be used before beginning study drug therapy, and for 4 months following discontinuation of study drug therapy~* Participants and/or their guardians must be willing and be capable of understanding risks and comply with the purpose of the study~Exclusion Criteria:~* Previous organ transplants~* Participants receiving multiple organs~* Participants requiring ventricular assist device (VAD) upon completion of transplantation surgery~* Women lactating, pregnant or of childbearing potential not using, or who are unwilling to use two reliable forms of contraception simultaneously during the study~* History of a psychological illness or condition which would interfere with the participant's ability to understand the requirements of the study~* White blood count =\<2500/mm\^3, platelets =\<50,000/mm\^3 or hemoglobin =\<6 g/dL~* HIV-1, the presence of positive HBsAg, or chronic active hepatitis C~* Active peptic ulcer disease~* Severe diarrhea or other gastrointestinal disorders which might interfere with their ability to absorb oral medication~* Malignancies within the past 5 years, excluding skin carcinoma that have been adequately treated~* Participants who have received within the past 30 days or require concomitant treatment with other investigational drugs or immunosuppressive medications that are prohibited for this study~* Inability to start microemulsion form of cyclosporine within 72 hours

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daclizumab (Type: EXPERIMENTAL): Daclizumab will be administered as a intravenous dose of 1 milligrams per kilogram \[mg/kg\] on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily \[BID\], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg, and 500-1000 mg IV methylprednisolone peri operative switch to oral at 0.5-1 mg/kg/day followed by tapering.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be administered on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily \[BID\], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg orally, and 500-1000 mg IV methylprednisolone peri-op switch to oral at 0.5-1 mg/kg/day followed by tapering.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Fibrinogen Concentrate Infusion on Blood Loss and Allogeneic Blood Conservation in Scoliosis Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients diagnosed as adolescent idiopathic scoliosis~* planed for elective posterior scoliosis correction surgery at Peking Union Medical College Hospital~Exclusion Criteria:~* preoperative anemia~* preoperative congenital or acquired coagulopathy~* ongoing anticoagulation therapy or drug intake that could cause bleeding~* clinical signs or diagnosis of acute thromboembolism~* emergency surgery~* redo surgery

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): The patients in treatment group will receive Fibrinogen Concentrate Human administration.
- Control group (Type: PLACEBO_COMPARATOR): The patients in control group will be administered with normal saline solution as placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil Only vs. Midazolam and Meperidine During Elective Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 19-65 years~* American Society of Anesthesiologists physical status (ASA PS) 1-2~* Patients scheduled for elective colonoscopy under Monitored Anesthesia Care in a University Hospital~* Patients who signed on written informed consent.~Exclusion Criteria:~* The exclusion criteria are refusal or inability to provide written informed consent~* Age \< 18 years~* Pregnancy~* Previous large bowel surgery~* Psychiatric disorders~* History of addiction to opiates and / or sedatives, and previous adverse reaction to any drug used in the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: EXPERIMENTAL): remifentanil of 0.04 mcg/kg/min with placebo (for midazolam) and placebo (for meperidine)
- midazolam and meperidine (Type: ACTIVE_COMPARATOR): a bolus midazolam of 0.03 mg/kg a bolus meperidine of 1.0 mg/kg placebo (for remifentanil)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who had blood prolactin level higher than 25ng/dl~Exclusion Criteria:~* Pregnancy~* Use of drugs effecting vasculature such as hormonal therapy, oral contraceptives, antihypertensives~* Diseases like pelvic inflammatory disease and systemic hypertension~* Women with clinically overt or treated cardiovascular disease~* Concurrent illness other than hyperprolactinemia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- pretreatment group (Type: NO_INTERVENTION): doppler evaluation at pretreatment period
- posttreatment group (Type: EXPERIMENTAL): doppler evaluatıon in normoprolactinemia women who given cabergoline treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* BMI greater than 85th percentile for age and gender~* Currently being treated with diet and exercise or metformin alone~* HbA1c (glycosylated haemoglobin) between 6.5 and 11.0%~Exclusion Criteria:~* Any clinically significant disease other than type 2 diabetes, as judged by the trial physician~* Previous treatment with any anti-diabetic drug other than metformin (except for prior short term treatment, at the discretion of the trial physician)

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- I.a (Type: EXPERIMENTAL): None
- I.b (Type: PLACEBO_COMPARATOR): None
- II.a (Type: EXPERIMENTAL): None
- II.b (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: INTRACEPT: Prospective, Randomized, Multi-center Study Intraosseous Basivertebral Nerve Ablation for Treatment of CLBP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Skeletally mature subjects at least 25 years of age~* Chronic lower back pain for at least 6 months~* Failure to respond to at least 6 months of non-operative conservative management~Exclusion Criteria:~* Radicular pain~* Current or history of spinal infection~* Modic changes at vertebral bodies other than L3 to S1~* Contraindication to MRI~* Pregnant, lactating or plan to become pregnant in next year~* Has life expectancy of less than 2 years~* Compensated injuries or ongoing litigation regarding back pain/injury, or financial incentive to remain impaired

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BVN Ablation (Type: ACTIVE_COMPARATOR): BVN ablation with continued standard care
- Standard Care Control (Type: ACTIVE_COMPARATOR): Continue with non-surgical standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of LDX on Functioning of College Students With ADHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic Statistical Manual of Mental Disorders 4th edition-text revision (DSM-IV-TR) criteria for ADHD based on self- and parent-report using questionnaires and clinical interview~Exclusion Criteria:~* significant cardiac condition based on medical history and/or physical examination~* significant substance abuse based on self-report and toxicology screen at intake~* significant symptoms of major depressive disorder, bipolar disorder, or thought disorder based on initial diagnostic interview

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 28 Years
- Healthy Volunteers: f

Study Arms:
- lisdexamfetamine dimesylate (Type: EXPERIMENTAL): All participants will be assessed across five conditions (baseline, placebo, 30-mg, 50-mg, \& 70-mg) in a double-blind, crossover design

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* 18-78 years of age~* Taking stable twice daily (BID) dosing of metformin IR (at least 1500 mg) for at least 8 weeks~* A1C: 7-10%~* C-peptide: ≥ 0.8 ng/mL~* Body mass index (BMI): ≤45 kg/m\^2~Exclusion Criteria:~* Women of childbearing potential unable or unwilling to use acceptable birth control~* Women who are pregnant or breastfeeding~* Fasting plasma glucose (FPG) \>270 mg/dL~* Significant cardiovascular history~* Symptoms of poorly controlled diabetes~* History of diabetic ketoacidosis or hyperosmolar nonketotic coma~* Insulin therapy within one year of screening~* Cardiovascular even within the prior 6 months~* New York Heart Association Stage III/IV congestive heart failure and/or known left ventricular ejection fraction \<=40%~* Significant history of renal or hepatic disease~* History of a psychiatric disorder, alcohol or drug abuse within the previous year~* Treatment with potent CYP3A4 inhibitors or inducers~* Immunocompromised participants~* Active liver disease or clinically significant abnormal hepatic, renal , endocrine, metabolic, or hematological screening tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin plus metformin IR (Type: ACTIVE_COMPARATOR): None
- Placebo plus metformin IR (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
\[Dose Escalation Part\]~Inclusion Criteria:~* Histological or cytological diagnosis of locally advanced or metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.~* ECOG Performance Status 0 or 1.~* Adequate Bone Marrow, Renal and Liver Function.~Exclusion Criteria:~* Patients with known symptomatic brain metastases requiring steroids.~* Current use of a strong P-gp inhibitor, strong P-gp inducer, or strong inhibitor of BCRP within 1 week or 5 half lives which ever is longer prior to the first dose of study treatment.~* Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.~\[Dose Expansion Part\]~Inclusion Criteria:~* Histologically or cytologically confirmed carcinoma of the breast.~* Locally advanced breast cancer that is not amenable to curative radiation or surgery and/or metastatic disease.~* Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation by Myriad Genetics' BRACAnalysis CDx test.~* No more than 3 prior chemotherapy-inclusive regimens for locally advanced or metastatic disease.~* Have measurable lesion by the RECIST v.1.1.~* ECOG Performance Status 0-2.~* Adequate Bone Marrow, Renal and Liver Function.~Exclusion Criteria:~* First-line locally advanced or metastatic breast cancer with no prior neoadjuvant and adjuvant chemotherapy.~* Prior treatment with a PARP inhibitor.~* Objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease.~* HER2 positive breast cancer.~* Active inflammatory breast cancer.~* Central nervous system (CNS) metastases.~* Current or anticipated use within 7 days prior to the first dose of study treatment, or anticipated use during the study of strong P-gp inhibitors.~* Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- talazoparib (Type: EXPERIMENTAL): 0.75 mg/day or 1.0 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete